Conference Dates: October 4 - 5, 2002
Conference Location: New York, New York, USA
Sponsoring Group: Imedex, Inc.
Conference Web Page URL: www.imedex.com/announcements/uslung02.htm
Topics Covered: Imaging and Surgical Staging in NSCLC, Management of Resectable Disease, Management of Metastatic/Recurrent Disease, Malignant Mesothelioma and Mediastinal Germ Cell Tumors, Esophageal Cancer, Small Cell Lung Cancer
Conference Objectives: After successfully completing this continuing medical education program participants should be able to:
Who Should Attend: This educational program is intended for oncologists, radiation therapists, thoracic surgeons and other physicians in active clinical practice interested and/or involved in the management of patients with thoracic cancer. No specialized knowledge or skills other than a general familiarity with cancer and its treatment is required for successful participation in this program.
Conference Fees: $225 by August 12; $325 by September 27; $425 after September 27. $99 Nurses, Residents and Fellows
Continuing Education: Yes
Miscellany: Imedex7 USA, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Imedex7 USA, Inc. designates this continuing medical education activity for a maximum of 15.5 credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
May 2, 2014 - For patients undergoing major pulmonary resection for lung cancer, low annual hospital volume is associated with increased 30-day and conditional 90-day mortality rates, according to a study presented at the annual meeting of the American Association for Thoracic Surgery, held from April 26 to 30 in Toronto.
Feb 20, 2012